Search the Newsreel

Landmark Property Development Company Ltd. (LPDC) Share Price Rises 12.24% Today

Melcor Developments Q2 Profit Rises

(RTTNews) - Melcor Developments (MRD.TO) released earnings for its second quarter that Increased, from the same period last year The company's bottom line came in at C$21.94 million, or C$0.73 per share. This compares with C$7.26 million, or C$0.24 per share, last year. The …

Melcor Developments announces second quarter results, declares quarterly dividend of $0.15 per share

DeFi Development Corp. (DFDV) swings to $110.7M loss on Solana strategy

DeFi Development Corp. (DFDV) reported a significant net loss of $110.7 million for the first half of 2026, primarily due to severe losses on its digital asset holdings and derivatives tied to Solana (SOL) financing. Despite a substantial increase in revenue from its Digital …

Kinetic Development Deepens Stake in MC Mining With US$16 Million Share Subscription and Bridge Loan

What's Going On With Genesis Land Development Corp. Stock Thursday?

CDB Financial Leasing Signs RMB1.3 Billion Wind Power Finance Lease

City Developments Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Autostreets Development Expects Swing to Loss in H1

NMDC vs Gujarat Mineral Development Corporation: Share Price, PE and ROE Compared

Generation Development Group (ASX:GDG) Reports Record AUD 46.4bn FUM Ahead of FY26 Results

Erdene Resource Development Corp (ERD) Earnings Preview — What to Watch Before the Report

Hong Kong's Hysan Development H1 profit rises 7.4%

Hysan Development Company: Recurring Underlying Profit up 1.7% and Underlying Profit up 7.4% on stable turnover and asset gains

SEC Rejects DeFi Development’s $1B Plan to Acquire Solana, But Vision Remains

The SEC has rejected DeFi Development's $1 billion plan to acquire Solana due to incomplete paperwork and eligibility issues, temporarily halting its ambition to become a major corporate holder of SOL. Despite this setback, the company remains committed to its vision, planning to refile …

How Investors Are Reacting To Peyto Exploration & Development (TSX:PEY) Stronger Year‑Over‑Year Earnings Momentum

DeFi Development Corp. to host May 2026 recap and AMA on X Spaces

DeFi Development Corp. will host a May 2026 Business Recap and AMA on June 11, 2026, at 11:00 AM ET via X Spaces. The event will cover treasury operations, capital markets activity, and Solana ecosystem updates, with leadership addressing live questions. This event follows …

What's Going On With Erdene Resource Development Corp Stock Wednesday?

Form 8K DeFi Development Corp For: 12 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by DeFi Development Corp for August 12. It briefly mentions the stock symbol DFDV and its performance, but provides no further details about the content of the 8K filing.

DeFi Development (NASDAQ:DFDV) Announces Earnings Results

DeFi Development (NASDAQ:DFDV) announced its earnings results, reporting a quarterly EPS of negative $0.21, a negative net margin of 1,136.38%, and a positive return on equity of 15.58%. Shares traded near the lower end of their 52-week range, with analysts maintaining a "Moderate Buy" …

DeFi Development Corp. (DFDV) grows SOL per share 24% despite Q2 2026 loss

DeFi Development Corp. (DFDV) reported a net loss of $27.287 million in Q2 2026 due to a significant change in digital asset valuation, despite revenue growing 66.9% year-over-year. The company increased its SOL per share (SPS) by 24% to 0.066, holding over 2.3 million …

DeFi Development Buys Back $3.5M Notes at 35% Discount

DeFi Development Corp. announced its Q2 2026 results, reporting a 24% year-over-year increase in SOL per share (SPS) to 0.066 and total SOL and equivalents of 2,311,523. The company also repurchased $3.5 million of its July 2030 convertible notes for $2.3 million, achieving a …

Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results, Beats Estimates By $0.26 EPS

Xilio Therapeutics (NASDAQ:XLO) announced its earnings results, reporting an adjusted loss of $0.33 per share, which beat analyst estimates by $0.26. The company's revenue of $18.69 million also surpassed expectations, though Xilio Therapeutics remains unprofitable with a negative net margin. Despite institutional investor ownership …

Xilio Therapeutics Releases Q2 2026 Financial Results

Xilio Therapeutics (XLO) reported its Q2 2026 financial results, showing a narrower net loss of $0.33 per share, an 85.3% improvement year-over-year. Revenue significantly increased by 131.2% to $18.7 million compared to Q2 2025. The company specializes in tumor-activated immuno-oncology therapies and continues to …

Goldman Sachs Group (TDAC) discloses 1,056,879 TDAC shares in 7.2% stake

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have reported a beneficial ownership of 1,056,879 Class A ordinary shares in Translational Development Acquisition Corp. (TDAC), representing a 7.2% stake. Both entities hold shared voting and shared dispositive power over …

DeFi Development Corp. Reports Q2 2026 Results, Grows SOL

DeFi Development Corp. (Nasdaq: DFDV) announced its Q2 2026 results, highlighting a 24% year-over-year growth in SOL per share (SPS) to 0.066 and a total of 2,311,523 SOL and equivalents. The company outlined Q3 cost efficiencies, capital structure simplification, and reaffirmed its long-term target …

Transcript : Peyto Exploration & Development Corp., Q2 2026 Earnings Call, Aug 12, 2026

Key Points Interested in Peyto Exploration & Development Corp.? Here are five stocks we like better. Q2 financial performance remained solid: Peyto generated C$228 million in funds from operations, reduced net debt by C$72 million and raised its monthly dividend by 9%, despite seasonal …

New City Development Group Clarifies Board and Committee Structure

New City Development Names Li Yang Co-CEO in Leadership Reshuffle

Form 8K Xilio Therapeutics Inc For: 12 August By Investing.com

This article reports on Xilio Therapeutics Inc.'s Form 8K filing for August 12. It notes the company's stock symbol as XLO, which saw a -1.42% change. The content primarily serves as a placeholder or announcement regarding the SEC filing.

Xilio Therapeutics reports Q2 2026: $18.7M collaboration revenue, $6.4M net loss, cash $136.0M

Xilio Therapeutics reported its Q2 2026 financial results, showing $18.7 million in collaboration revenue and a net loss of $6.4 million. The company held $136.0 million in cash and cash equivalents, expecting this to fund operations into Q1 2028. Key business highlights include FDA …

Xilio expects to dose cancer patients with XTX501 in H2 2026

Xilio Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including FDA clearance for XTX501, a bispecific PD-1 / masked IL-2, with dosing expected in H2 2026. The company also announced advancing IND-enabling studies for two masked T cell engager …

China Tianbao Warns of Wider Interim Loss on Lower Construction Revenue

Earnings Flash (PEY.TO) Peyto Exploration & Development Corp. Posts Q2 Adjusted EPS C$0.50

Kinetic Development Sets Board Meeting to Review Interim Results and Dividend

William Blair Maintains NioCorp Developments(NB.US) With Buy Rating

William Blair has reiterated its Buy rating on NioCorp Developments (NB.US). This indicates a continued positive outlook from the firm regarding NioCorp Developments' stock performance and prospects.